These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Intravital microscopic characterization of suramin effects in an orthotopic immunocompetent rat model of pancreatic cancer. Hotz B; Buhr HJ; Hotz HG J Gastrointest Surg; 2008 May; 12(5):900-6. PubMed ID: 18320288 [TBL] [Abstract][Full Text] [Related]
3. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324 [TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. Bangard C; Gossmann A; Papyan A; Tawadros S; Hellmich M; Bruns CJ Int J Cancer; 2005 Mar; 114(1):131-8. PubMed ID: 15523683 [TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976 [TBL] [Abstract][Full Text] [Related]
6. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819 [TBL] [Abstract][Full Text] [Related]
7. Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging. Faccioli N; Marzola P; Boschi F; Sbarbati A; D'Onofrio M; Pozzi Mucelli R Radiol Med; 2007 Apr; 112(3):319-28. PubMed ID: 17440699 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model. Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057 [TBL] [Abstract][Full Text] [Related]
9. MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats. Fournier LS; Novikov V; Lucidi V; Fu Y; Miller T; Floyd E; Shames DM; Brasch RC Radiology; 2007 Apr; 243(1):105-11. PubMed ID: 17329684 [TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced MRI in head-and-neck cancer: the impact of region of interest selection on the intra- and interpatient variability of pharmacokinetic parameters. Craciunescu OI; Yoo DS; Cleland E; Muradyan N; Carroll MD; MacFall JR; Barboriak DP; Brizel DM Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e345-50. PubMed ID: 21985945 [TBL] [Abstract][Full Text] [Related]
11. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064 [TBL] [Abstract][Full Text] [Related]
12. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model. Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145 [TBL] [Abstract][Full Text] [Related]
13. [Effects of MRI-assayed microvascular permeability on the accumulation of vinorelbine in xenograft tumors]. Raatschen HJ; Fu Y; Rogut V; Simon GH; Sennino B; Wolf KJ; Brasch RC Rofo; 2010 Feb; 182(2):133-9. PubMed ID: 19862658 [TBL] [Abstract][Full Text] [Related]
14. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content. Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159 [TBL] [Abstract][Full Text] [Related]
15. Monitoring of bevacizumab-induced antiangiogenic treatment effects by "steady state" ultrasmall superparamagnetic iron oxide particles magnetic resonance imaging using robust multiecho ΔR2* relaxometry. Ring J; Persigehl T; Remmele S; Heindel W; Dahnke H; Bremer C Invest Radiol; 2011 May; 46(5):326-30. PubMed ID: 21358548 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of pancreatic cancer by multiple breath-hold dynamic contrast-enhanced magnetic resonance imaging at 3.0T. Yao X; Zeng M; Wang H; Sun F; Rao S; Ji Y Eur J Radiol; 2012 Aug; 81(8):e917-22. PubMed ID: 22695786 [TBL] [Abstract][Full Text] [Related]
17. GPU-accelerated nonparametric kinetic analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab. Hsu YH; Ferl GZ; Ng CM Magn Reson Imaging; 2013 May; 31(4):618-23. PubMed ID: 23200680 [TBL] [Abstract][Full Text] [Related]